

WHAT IS CLAIMED IS:

1. A liquid formulation of a therapeutic agent comprising:
5 rapamycin in a pharmaceutically effective dosage; and
one or more pharmaceutically acceptable solubility enhancers.
2. The liquid formulation according to claim 1, further comprising
one or more pharmaceutically acceptable stabilizers.
- 10 3. The liquid formulation according to claim 2, wherein the
concentration of rapamycin in solution is in the range from about 1 mg/ml to
about 15 mg/ml.
- 15 4. The liquid formulation according to claim 3, wherein the
rapamycin comprises sirolimus.
5. The liquid formulation according to claim 3, wherein the
rapamycin comprises CCI-779.
- 20 6. The liquid formulation according to claim 2, wherein the one or
more pharmaceutically acceptable stabilizer and solubility enhancers
comprises polyethylene glycol.
- 25 7. The liquid formulation according to claim 2, wherein the one or
more pharmaceutically acceptable stabilizer and solubility enhancers
comprises Vitamin E TPGS.
8. The liquid formulation according to claim 1, further comprising
30 water.
9. A method for the treatment of vascular disease comprising the
administration of a liquid formulation of rapamycin proximate the disease site.

10. The method for the treatment of vascular disease according to claim 9, wherein the liquid formulation of rapamycin comprises rapamycin in a pharmaceutically effective dosage and one or more pharmaceutically acceptable solubility enhancers.

5